Treatment and developmental therapeutics in aspergillosis. 2. Azoles and other antifungal drugs.
The present article surveys the anti-Aspergillus activity of various azole derivatives as well as a number of miscellaneous other antifungal agents. The drawbacks of sodium (potassium) iodide therapy in the management of pulmonary aspergilloma are discussed along with current efforts at treatment of allergic bronchopulmonary aspergillosis and Aspergillus-induced otomycosis.
Georgiev
V S
VS
National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892.
D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use; D001228:Aspergillosis / Q000188:drug therapy*; D001229:Aspergillosis, Allergic Bronchopulmonary / Q000188:drug therapy; D001393:Azoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003022:Clotrimazole / Q000627:therapeutic use; D004195:Disease Models, Animal; D015725:Fluconazole / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D007654:Ketoconazole / Q000627:therapeutic use; D008172:Lung Diseases, Fungal / Q000188:drug therapy*; D008825:Miconazole / Q000627:therapeutic use; D010032:Otitis Externa / Q000188:drug therapy
D000935:Antifungal Agents; D001393:Azoles; D007093:Imidazoles; D008825:Miconazole; D015725:Fluconazole; D003022:Clotrimazole; D007654:Ketoconazole